Zydus Lifesciences reported better-than-estimated numbers on Friday led by its US and India business along with contributions from Europe, API and Emerging Market divisions.

Share Market Live

NSE

The company's December quarter results were a beat on all parameters compared to CNBC-TV18 estimates compiled from various analysts. Revenue increased 20 percent from last year while EBITDA margin expanded 130 basis points.

R&D expenses for the quarter stood at 8 percent of overall sales.

Zydus' US business, which comprises of 46 percent of the overall topline stood at a multi-quarter high of $235 million, a growth of 29 percent from last year.

The India business, which makes up for 40 percent of sales, grew 12.5 percent compared to last year, but declined on a sequential basis. Within the India business, formulations grew 14.2 percent while consumer wellness business increased nearly 8 percent year-on-year. However, both businesses declined compared to the September quarter.

Zydus' Emerging Markets and European business grew in low-to-mid-single-digits while the API business, which makes up for 4 percent of overall sales, saw revenue growth of 14 percent year-on-year.

Shares of Zydus Life ended 0.4 percent higher at Rs 434.75.

(Edited by : Rukmani Krishna)